Profile: GlaxoSmithKline PLC (GSK)
15 Sep 2014
GlaxoSmithKline plc (GSK), incorporated on December 6, 1999, is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 31, 2012, the Company completed the divestment of brands in the United States and Canada to Prestige Brands Holdings. The brands included BC, Goody’s, Beano, Ecotrin, FiberChoice and Tagamet. In August 2012, it acquired Human Genome Sciences. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd. In May 2013, GlaxoSmithKline PLC acquired Okairos AG. In December 2013, Suntory Beverage & Food Ltd fully acquired Lucozade Ribena Suntory Limited from GlaxoSmithKline plc.
GSK’s Pharmaceuticals business develops and makes available medicines to treat a range of serious and chronic diseases. The Company operates in geographical segments that combine these two businesses: its Consumer Healthcare business functions as a global unit, as does ViiV Healthcare, the specialist HIV Company. . Its Vaccines business produces paediatric and adult vaccines against a range of infectious diseases. In 2012, the Company distributed 900 million doses to 170 countries. GSK’s principal pharmaceutical products are directed to therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, anti-bacterials, oncology, Vaccines and HIV. The Company’s products for respiratory therapeutic area Flixotide/Flovent, Seretide/Advair, Serevent and Ventolin HFA. Its products for anti-virals are Relenza, Valtrex and Zeffix/Epivir-HBV. The Company’s products for central nervous system are Lamictal, Imigran/Imitrex, Requip XL, Seroxat/Paxil, Treximet and Wellbutrin. The Company’s products for cardiovascular and urogenital areas include Arixtra, Avodart, Benlysta, Coreg CR, Fraxiparine, Lovaza and Volibris. Augmentin is GSK’s anti-bacterial product. Its Oncology products are Arzerra, Hycamtin, Promacta/ Revolade, Tykerb/Tyverb and Votrient. The Company’s vaccines are Boostrix, Infanrix/Pediarix, Cervarix, Fluarix, FluLaval, Pandemrix, Prepandrix and Synflorix. GSK’s HIV products are Combivir, Epivir, Epzicom/Kivexa, Lexiva, Selzentry and Trizivir.
The Company competes with Abbott Laboratories, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, Roche Holdings, Sanofi, Takeda and Teva Pharmaceuticals.
Consumer Healthcare products
The Company develops and markets a range of consumer health products. Its three main categories are Over-the-counter (OTC) medicines, Oral healthcare and Nutritional healthcare. The Company’s portfolio includes a number of brands, such as Panadol, Sensodyne, Lucozade and Horlicks. The OTC medicines are Panadol, which includes tablets, capulets, infant drops; NicoDerm, NiQuitin CQ, and Nicabate, which includes gum, patch, mini lozenge, original lozenge, and also Nicorette. Oral healthcare products of the Company are Sensodyne, a range of toothpastes, toothbrushes and mouthwashes; Polident, Poligrip and Corega, the denture adhesive and denture cleanser, and Aquafresh, a range of toothpastes and toothbrushes. Nutritional healthcare products include Lucozade, a range of energy and sports drinks, and Horlicks, malted food milk-based drinks and foods.
The Company competes with Colgate-Palmolive, Johnson & Johnson, Procter & Gamble, Unilever, Pfizer and Novartis.
980 Great West Road
BRENTFORD ENG TW8 9GS
Company Web Links
- Exclusive: GSK China consumer healthcare unit linked to DOJ probe in 2012
- UPDATE 1-Cost a focus as GSK takes lead in new wave of biotech lung drugs
- BRIEF-GSK, GOLD, COPD foundation to form expert governance board for COPD assessment test
- BRIEF-GSK, Gilead drug combo helps in pulmonary arterial hypertension
- BRIEF-GSK announces publication of positive study results for Mepolizumab